Seegehalli M Anil1, Nurit Shalev1, Ajjampura C Vinayaka1, Stalin Nadarajan1, Dvora Namdar1, Eduard Belausov1, Irit Shoval2, Karthik Ananth Mani3, Guy Mechrez3, Hinanit Koltai4. 1. Institute of Plant Science, Agriculture Research Organization, Volcani Center, 7528809, Rishon LeZion, Israel. 2. The Mina & Everard Goodman Faculty of Life Sciences, Bar-Ilan University, 5290002, Ramat Gan, Israel. 3. Institute for Postharvest and Food Science, Agriculture Research Organization, Volcani Center, 7528809, Rishon LeZion, Israel. 4. Institute of Plant Science, Agriculture Research Organization, Volcani Center, 7528809, Rishon LeZion, Israel. hkoltai@agri.gov.il.
Abstract
Cannabis sativa is widely used for medical purposes and has anti-inflammatory activity. This study intended to examine the anti-inflammatory activity of cannabis on immune response markers associated with coronavirus disease 2019 (COVID-19) inflammation. An extract fraction from C. sativa Arbel strain (FCBD) substantially reduced (dose dependently) interleukin (IL)-6 and -8 levels in an alveolar epithelial (A549) cell line. FCBD contained cannabidiol (CBD), cannabigerol (CBG) and tetrahydrocannabivarin (THCV), and multiple terpenes. Treatments with FCBD and a FCBD formulation using phytocannabinoid standards (FCBD:std) reduced IL-6, IL-8, C-C Motif Chemokine Ligands (CCLs) 2 and 7, and angiotensin I converting enzyme 2 (ACE2) expression in the A549 cell line. Treatment with FCBD induced macrophage (differentiated KG1 cell line) polarization and phagocytosis in vitro, and increased CD36 and type II receptor for the Fc region of IgG (FcγRII) expression. FCBD treatment also substantially increased IL-6 and IL-8 expression in macrophages. FCBD:std, while maintaining anti-inflammatory activity in alveolar epithelial cells, led to reduced phagocytosis and pro-inflammatory IL secretion in macrophages in comparison to FCBD. The phytocannabinoid formulation may show superior activity versus the cannabis-derived fraction for reduction of lung inflammation, yet there is a need of caution proposing cannabis as treatment for COVID-19.
class="Species">Cannabis sativa is widely used for medical purposes and has anti-inflammatory activity. This study intended to expan class="Chemical">amine the anti-inflammatory activity of cannabis on immune response markers associated with coronavirus disease 2019 (COVID-19) inflammation. An extract fraction from C. sativa Arbel strain (FCBD) substantially reduced (dose dependently) interleukin (IL)-6 and -8 levels in an alveolar epithelial (A549) cell line. FCBD contained cannabidiol (CBD), cannabigerol (CBG) and tetrahydrocannabivarin (THCV), and multiple terpenes. Treatments with FCBD and a FCBD formulation using phytocannabinoid standards (FCBD:std) reduced IL-6, IL-8, C-C Motif Chemokine Ligands (CCLs) 2 and 7, and angiotensin I converting enzyme 2 (ACE2) expression in the A549 cell line. Treatment with FCBD induced macrophage (differentiated KG1 cell line) polarization and phagocytosis in vitro, and increased CD36 and type II receptor for the Fc region of IgG (FcγRII) expression. FCBD treatment also substantially increased IL-6 and IL-8 expression in macrophages. FCBD:std, while maintaining anti-inflammatory activity in alveolar epithelial cells, led to reduced phagocytosis and pro-inflammatory IL secretion in macrophages in comparison to FCBD. The phytocannabinoid formulation may show superior activity versus the cannabis-derived fraction for reduction of lung inflammation, yet there is a need of caution proposing cannabis as treatment for COVID-19.
Authors: Grace E Cooper; Zoe C Pounce; Joshua C Wallington; Leidy Y Bastidas-Legarda; Ben Nicholas; Chiamaka Chidomere; Emily C Robinson; Kirstin Martin; Anna S Tocheva; Myron Christodoulides; Ratko Djukanovic; Tom M A Wilkinson; Karl J Staples Journal: PLoS One Date: 2016-10-04 Impact factor: 3.240
Authors: Yan Wang; Gladys E Ibañez; Krishna Vaddiparti; Nichole E Stetten; Ruba Sajdeya; Eric C Porges; Ronald A Cohen; Robert L Cook Journal: Drug Alcohol Depend Date: 2021-05-21 Impact factor: 4.852
Authors: Ali A Rabaan; Shamsah H Al-Ahmed; Mohammed A Garout; Ayman M Al-Qaaneh; Anupam A Sule; Raghavendra Tirupathi; Abbas Al Mutair; Saad Alhumaid; Abdulkarim Hasan; Manish Dhawan; Ruchi Tiwari; Khan Sharun; Ranjan K Mohapatra; Saikat Mitra; Talha Bin Emran; Muhammad Bilal; Rajendra Singh; Salem A Alyami; Mohammad Ali Moni; Kuldeep Dhama Journal: Pathogens Date: 2021-05-07
Authors: Dóra Révész; Genís Ona; Giordano N Rossi; Juliana M Rocha; Rafael G Dos Santos; Jaime E C Hallak; Miguel Á Alcázar-Córcoles; José C Bouso Journal: Front Psychiatry Date: 2021-06-16 Impact factor: 5.435
Authors: Lior Chatow; Adi Nudel; Iris Nesher; David Hayo Hemo; Perri Rozenberg; Hanna Voropaev; Ilan Winkler; Ronnie Levy; Zohar Kerem; Zohara Yaniv; Nadav Eyal Journal: Life (Basel) Date: 2021-03-29
Authors: Pedro Augusto Lopes Tito; Túlio Cézar de Souza Bernardino; Paula Maria Quaglio Bellozi; Maria Carolina Machado da Silva; Aline Silva de Miranda; Érica Leandro Marciano Vieira; Fabrício A Moreira; András Palotás; Antônio Carlos Pinheiro de Oliveira; Helton José Reis Journal: Pharmacol Rep Date: 2021-07-03 Impact factor: 3.024